Laboratoires Filorga, a company with a long expertise in aesthetic medicine, announces it has bought 48% of the shares of the MOSTLeds capital. MOSTLeds develops, manufactures and puts on the market a disruptive technology in the areas of aesthetic medicine and of the well-being: the LED photobiomodulation.
According to the press release, the MOSTLeds technology added to the Filorga expertise allows to forecast important synergies, on the business development level as well as in the research and development of products specific to phototherapy for medical, functional rehabilitation, aesthetic, thalasso-therapy and spa applications. With this technology acquisition, Filorga will be able to enhance the approach of its combined therapies, blending the different techniques of medical rejuvenation (hyaluronic acid injections, anti-ageing meso-therapy, glycolic peeling, and, now, LED photo-biostimualtion), to get the most harmonious, efficient and natural anti-ageing results.
The devices developed by MOSTLeds are based on a specific network of LEDs that provides a very high irradiance, for an increased efficiency of the treatment of stretch marks, acne, scars, pains, face and body cutaneous ageing, burns, cellulite, and in phototherapy used in oncology.
Laboratoires Filorga is currently present on the aesthetic medicine market (injectable, hyaluronic acid-based products for the filling of wrinkles, mesotherapy and peeling) for dermatologists, aesthetic M.Ds and plastic surgeons. Laboratoires Filorga has also launched, for the public at large, a cosmetics programme of 19 references, with novel formulae and high-tech ingredients, thanks to the company’s expertise in cutaneous ageing.
This programme is now available in more …
